Cargando…
Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
Idelalisib, a PI3K inhibitor, specifically targeting p110δ, has been approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. However, the mechanisms of action of idelalisib in colon cancer cells are not well understood. We investigated how idela...
Autores principales: | Yang, Shida, Zhu, Zhiyong, Zhang, Xiaobing, Zhang, Ning, Yao, Zhicheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351616/ https://www.ncbi.nlm.nih.gov/pubmed/28008149 http://dx.doi.org/10.18632/oncotarget.14043 |
Ejemplares similares
-
NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction
por: Yang, Shida, et al.
Publicado: (2017) -
Retraction Note: Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway
por: Yang, Shida, et al.
Publicado: (2022) -
The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA
por: Sun, Jing, et al.
Publicado: (2012) -
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022) -
Trastuzumab induces PUMA‐dependent apoptosis and inhibits tumor growth in gastric cancer
por: Luo, Linghe, et al.
Publicado: (2018)